Dual effect of erbB-2 depletion on the regulation of DNA repair and cell cycle mechanisms in non-small cell lung cancer cells
- PMID: 9872333
- DOI: 10.1038/sj.onc.1202246
Dual effect of erbB-2 depletion on the regulation of DNA repair and cell cycle mechanisms in non-small cell lung cancer cells
Abstract
Overexpression of the erbB-2 tyrosine kinase receptor, p185erbB-2, is a common alteration in non-small cell lung cancer (NSCLC) and has been associated with poor prognosis and a tumor drug resistance phenotype. In this study, we have examined the consequences of erbB-2 depletion on DNA repair, cell cycle, and apoptosis using a panel of NSCLC cell lines constitutively overexpressing erbB-2 receptor. Depletion of the erbB-2 was achieved using the tyrosine kinase inhibitor CP127,374 which promotes erbB-2 degradation. Treatment with CP127,374 concentrations which deplete erbB-2 and inhibit tyrosine phosphorylation resulted in downregulation of DNA repair mechanisms and cell accumulation at G1 phase of the cell cycle. GI arrest was observed in cells with mutated p53 as well as cells lacking p53 protein, suggesting a p53-independent mechanisms. NSCLC cells which overexpress erbB-2 were more resistant to cisplatin-induced cytotoxicity in comparison to cells expressing low levels of erbB-2. Treatment with CP127,374 alone did not result in any induction of apoptosis. A combination of CP127,374 and cisplatin, however, was more potent in cell growth inhibition and induction of apoptosis compared to treatment with cisplatin alone. Together, our results further support a pivotal role of erbB-2 signaling in the regulatory balance between DNA repair, cell cycle checkpoints and apoptosis; all these mechanisms are essential determinants for tumor cell destiny following chemotherapy stress.
Similar articles
-
Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185(erbB-2) is dependent on the ras signaling pathway.Oncogene. 1997 Apr 17;14(15):1827-35. doi: 10.1038/sj.onc.1201019. Oncogene. 1997. PMID: 9150389
-
Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.Cancer Res. 1999 Mar 15;59(6):1347-55. Cancer Res. 1999. PMID: 10096569
-
Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin.Oncogene. 1996 Feb 1;12(3):571-6. Oncogene. 1996. PMID: 8637714
-
The role of ErbB-2 tyrosine kinase receptor in cellular intrinsic chemoresistance: mechanisms and implications.Biochem Cell Biol. 1997;75(4):315-25. Biochem Cell Biol. 1997. PMID: 9493954 Review.
-
[Cell cycle regulation after exposure to ionizing radiation].Bull Cancer. 1999 Apr;86(4):345-57. Bull Cancer. 1999. PMID: 10341340 Review. French.
Cited by
-
Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.Crit Rev Oncol Hematol. 2010 Sep;75(3):173-234. doi: 10.1016/j.critrevonc.2009.11.006. Epub 2010 Jan 4. Crit Rev Oncol Hematol. 2010. PMID: 20047843 Free PMC article. Review.
-
Regulation of focal adhesion turnover by ErbB signalling in invasive breast cancer cells.Br J Cancer. 2009 Feb 24;100(4):633-43. doi: 10.1038/sj.bjc.6604901. Epub 2009 Feb 3. Br J Cancer. 2009. PMID: 19190626 Free PMC article.
-
Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers.Mol Biol Cell. 2002 Nov;13(11):4029-44. doi: 10.1091/mbc.e02-02-0084. Mol Biol Cell. 2002. PMID: 12429844 Free PMC article.
-
Tyrosine kinase inhibitors: a clinical perspective.Curr Oncol Rep. 2002 Jan;4(1):9-19. doi: 10.1007/s11912-002-0043-x. Curr Oncol Rep. 2002. PMID: 11734109 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous